Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program

Donatella Regano, Alessia Visintin, Fabiana Clapero, Federico Bussolino, Donatella Valdembri, Federica Maione, Guido Serini, Enrico Giraudo

Research output: Contribution to journalArticlepeer-review


OBJECTIVE—: Molecular pathways governing blood vessel patterning are vital to vertebrate development. Because of their ability to counteract proangiogenic factors, antiangiogenic secreted Sema3 (class 3 semaphorins) control embryonic vascular morphogenesis. However, if and how Sema3 may play a role in the control of extraembryonic vascular development is presently unknown. APPROACH AND RESULTS—: By characterizing genetically modified mice, here, we show that surprisingly Sema3F acts instead as a selective extraembryonic but not intraembryonic proangiogenic cue. Both in vivo and in vitro, in visceral yolk sac epithelial cells, Sema3F signals to inhibit the phosphorylation-dependent degradation of Myc, a transcription factor that drives the expression of proangiogenic genes, such as the microRNA cluster 17/92. In Sema3f-null yolk sacs, the transcription of Myc-regulated microRNA 17/92 cluster members is impaired, and the synthesis of Myc and microRNA 17/92 foremost antiangiogenic target Thbs1 (thrombospondin 1) is increased, whereas vascular endothelial growth factor signaling is inhibited in yolk sac endothelial cells. Consistently, exogenous recombinant Sema3F inhibits the phosphorylation-dependent degradation of Myc and the synthesis of Thbs1 in mouse F9 teratocarcinoma stem cells that were in vitro differentiated in visceral yolk sac epithelial cells. Sema3f mice placentas are also highly anemic and abnormally vascularized. CONCLUSIONS—: Sema3F functions as an unconventional Sema3 that promotes extraembryonic angiogenesis by inhibiting the Myc-regulated synthesis of Thbs1 in visceral yolk sac epithelial cells.Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Original languageEnglish
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Publication statusAccepted/In press - Jul 20 2017

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Sema3F (Semaphorin 3F) Selectively Drives an Extraembryonic Proangiogenic Program'. Together they form a unique fingerprint.

Cite this